123742-32-5

Upstream product

• 62642-62-0 4-(morpholinomethyl)benzoic acid 
• 68453-56-5 methyl 4-(morpholinomethyl)benzoate 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 1571-08-0 methyl 4-formylbenzoate 
• 65101-82-8 4-(4-morpholinylmethyl)benzoic acid hydrochloride 

Downstream Products

• 929622-08-2 Bavisant 
• 321915-62-2 N,N'-diformyl-N,N'-di[1-methyl-2-S-(p-morpholinomethylphenylcarboxy)-thio-4-methoxybut-1-enyl]-1,12-diaminododecane 
• 1327167-34-9 N-(3-(3-[(phenylsulfonyl)amino]phenyl)-1H-pyrazol-5-yl)-4-(morpholinomethyl)benzamide 
• 1202967-76-7 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylbenzoylamino)isoxazole-3-carboxylic acid ethylamide 

Relevant academic research and scientific papers

New acyl derivatives of 3-aminofurazanes and their antiplasmodial activities

An N-acylated furazan-3-amine of a Medicines for Malaria Venture (MMV) project has shown activity against different strains of Plasmodium falciparum. Seventeen new derivatives were prepared and tested in vitro for their activities against blood stages of two strains of Plasmodium falciparum. Several structure–activity relationships were revealed. The activity strongly depended on the nature of the acyl moiety. Only benzamides showed promising activity. The substitution pattern of their phenyl ring affected the activity and the cytotoxicity of compounds. In addition, physicochemical parameters were calculated (log P, log D, ligand efficiency) or determined experimentally (permeability) via a PAMPA. The N-(4-(3,4-diethoxyphenyl)-1,2,5-oxadiazol-3-yl)-3(trifluoromethyl)benzamide possessed good physicochemical properties and showed high antiplasmodial activity against a chloroquine-sensitive strain (IC50 (NF54) = 0.019 μM) and even higher antiplasmodial activity against a multiresistant strain (IC50 (K1 ) = 0.007 μM). Compared to the MMV compound, the permeability and the activity against the multiresistant strain were improved.

Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections

The recent Ebola epidemics in West Africa underscore the great need for effective and practical therapies for future Ebola virus outbreaks. We have discovered a new series of remarkably potent small molecule inhibitors of Ebola virus entry. These 4-(aminomethyl)benzamide-based inhibitors are also effective against Marburg virus. Synthetic routes to these compounds allowed for the preparation of a wide variety of structures, including a conformationally restrained subset of indolines (compounds 41-50). Compounds 20, 23, 32, 33, and 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses. Representative compounds (20, 32, and 35) have shown good metabolic stability in plasma and liver microsomes (rat and human), and 32 did not inhibit CYP3A4 nor CYP2C9. These 4-(aminomethyl)benzamides are suitable for further optimization as inhibitors of filovirus entry, with the potential to be developed as therapeutic agents for the treatment and control of Ebola virus infections.

Trans-bond energy transfer type hypochlorous acid fluorescent probe and application thereof to detection of lysosome hypochlorous acid

The invention discloses a trans-bond energy transfer-based hypochlorous acid ratio fluorescent probe. The probe takes imidazo[1,5-a]pyridine as an energy donor, rhodamine as an energy receptor and thiodihydrazide as a hypochlorous acid response group; a m

Preparation and application of fluorescence probe applied to HOCl detection in lysosome

The invention discloses a fluorescence probe applied to HOCl detection in lysosome. The probe takes imidazo[1,5-a]pyridine as an energy donor, rhodamine as an energy receptor, thiodihydrazide structure as a response group of hypochlorous acid and a morpho

A fluorescent probe for the detection of HOCl in lysosomes

In this study, a new fluorescent probe (LR1) for lysosomal HOCl was developed by integrating a morpholine moiety, a lysosome-targeting group, into the rhodamine framework. LR1 exhibited remarkable fluorescence intensity enhancement at 582 nm upon HOCl tit

Preparation and application of rhodamine hypochlorous acid fluorescent probe capable of targeting lysosome

The invention discloses a rhodamine hypochlorous acid fluorescent probe capable of targeting a lysosome. According to the probe, a morpholine structure is used as a locating group of the lysosome, when hypochlorous acid exists, a rhodamine group is conver

Rhodamine B type fluorescent probe capable of being applied to detection of HOCl in cytolysosome

The invention discloses a rhodamine B type fluorescent probe capable of being applied to detection of HOCl in cytolysosome. The probe takes rhodamine B as fluorophore and thiodihydrazide as a responsegroup; a morpholine structure is introduced into a prob

Tetrahydrobenzothiophene carboxamides: Beyond the kinase domain and into the fatty acid realm

A series of tetrahydrobenzothiophene carboxamides, inspired by structural features present in kinase and SCD1 inhibitors, are presented here. Prototype compound 8 (MMDD13) modulates fatty acid elongase and desaturase indexes, lipid accumulation, while pre

Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors.

Synthesis of N-aryl benzamides containing pharmacophoric tyrosine kinase inhibitor fragments

New N-aryl 4-(arylaminomethyl)benzamides containing pharmacophoric heterocyclic fragments have been synthesized from 2-arylaminopyrimidine, 1-methylpiperazine, and morpholine derivatives and substituted benzoic acids.